New cardiac ryanodine receptor inhibitors for the treatment of heart failure

新型心脏兰尼碱受体抑制剂用于治疗心力衰竭

• 批准号: nhmrc : 1008477
• 负责人: A/Pr Marco Casarotto
• 金额: $ 40.87万
• 依托单位: Australian National University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/new-cardiac-ryanodine-heart-failure/109317
• 关键词: New; cardiac; ryanodine; receptor; inhibitors

We have discovered that a protein that is recognized for its role in phase II detoxification can also modify the calcium signaling that underlies heart function. The small part of the protein that is active in heart tissue differs from the enzyme center that supports detoxification and can thus be used as a therapeutic agent in heart failure and in genetic cardiac conditions. The project is to develop the cardio-active part of the protein for maximum efficacy and for eventual clinical use.

我们发现，一种在II期解毒中发挥作用的蛋白质也可以改变心脏功能所依赖的钙信号。在心脏组织中有活性的蛋白质的一小部分与支持解毒的酶中心不同，因此可以用作心力衰竭和遗传性心脏病的治疗剂。该项目旨在开发蛋白质的心脏活性部分，以获得最大功效并最终用于临床。